ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer

Virchows Archiv

Volumn 461, Issue 2, 2012, Pages 157-162

  Scheble, Veit J ^a   Scharf, Gregor ^a   Braun, Martin ^c   Ruiz, Christian ^b   Stürm, Susanna ^b   Petersen, Karen ^a   Beschorner, Rudi ^a   Bachmann, Alexander ^d   Zellweger, Tobias ^e   Fend, Falko ^a   Kristiansen, Glen ^c   Bubendorf, Lukas ^b   Wernert, Nicolas ^c   Adler, David ^c   Perner, Sven ^a,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e St Claraspital AG   (Switzerland)

Author keywords

Androgen receptor; Castration resistant prostate cancer; ERG rearrangement; Hormone refractory prostate cancer; Metastatic cancer; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; TRANSCRIPTION FACTOR ERG;

ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 84867400536     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1270-7     Document Type: Article

References (27)

1. Attard G, Sarker D, Reid A, Molife R, Parker C, De Bono JS (2006) Improving the outcome of patients with castrationresistant prostate cancer through rational drug development. Br J Cancer 95(7):767-774. doi:10.1038/sj.bjc.6603223 (Pubitemid 44498089)
2. Appleman LJ (2010) Castration-refractory prostate cancer: new therapies, new questions. Oncology (Williston Park) 24(14):1318-1319, 1326
3. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG (2009) Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15(14):4706-4711. doi:10.1158/1078-0432. CCR-08-2927
4. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644-648. doi:10.1126/science.1117679 (Pubitemid 41528150)
5. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG (2011) Combining urinary detection of TMPRSS2: ERG and CaP3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol. doi:10.1016/j.urolonc.2011.04.001
6. He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S, Smith K, Rubin MA, Zhou M (2011) The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". Am J Surg Pathol 35(4):608-614. doi:10.1097/PAS.0b013e31820bcd2d
7. Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, Elsamanoudi S, Brassell S, Furusato B, Stingle N, Sesterhenn IA, Petrovics G, Miick S, Rittenhouse H, Groskopf J, McLeod DG, Srivastava S (2010) Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res 16(5):1572-1576. doi:10.1158/1078-0432. CCR-09-2191
8. Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S (2010) ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 23(8):1061-1067. doi:10.1038/modpathol.2010.87
9. Braun M, Scheble V, Menon R, Scharf G, Wilbertz T, Petersen K, Beschorner C, Reischl M, Kuefer R, Schilling D, Stenzl A, Kristiansen G, Rubin M, Fend F, Perner S (2011) Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology (in press)
10. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA (2009) ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56(2):275-286. doi:10.1016/j.eururo.2009.04.036
11. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA (2011) TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 42(1):11-17. doi:10.1016/j.humpath.2010.05.026
12. Scheble VJ, Braun M, Wilbertz T, Stiedl AC, Petersen K, Schilling D, Reischl M, Seitz G, Fend F, Kristiansen G, Perner S (2010) ERG rearrangement in small cell prostatic and lung cancer. Histopathology 56(7):937-943. doi:10.1111/j.1365-2559.2010.03564.x
13. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31(6):882-888. doi:10.1097/01.pas.0000213424.38503.aa00000478-200706000- 00008 (Pubitemid 47165141)
14. Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin MA (2010) ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 75(4):762-767. doi:10.1016/j.urology.2009.10.010
15. Feldman BJ, Feldman D (2001) The development of androgenindependent prostate cancer. Nat Rev Cancer 1(1):34-45
16. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59(4):803-806 (Pubitemid 29086730)
17. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9(4):401-406. doi:10.1038/ng0495-401
18. Cai C, Wang H, Xu Y, Chen S, Balk SP (2009) Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 69(15):6027-6032. doi:10.1158/0008-5472. CAN-09-0395
19. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB (2009) Fluorescence in situ hybridization study shows association of PTEN deletionwith ERGrearrangement during prostate cancer progression. Mod Pathol 22(8):1083-1093. doi:10.1038/modpathol.2009.69
20. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramaki OR, Visakorpi T (2010) Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrinetreated prostate cancer. Clin Cancer Res 16(10):2845-2851. doi:10.1158/1078-0432. CCR-09-2505
21. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM (2008) Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68(10):3584-3590. doi:10.1158/0008-5472. CAN-07-6154
22. Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR, Sircar K, Chinnaiyan AM, Bismar TA, Rubin MA, Demichelis F (2010) ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 12(12):1031-1040
23. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T (2008) TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 14(11):3395-3400. doi:10.1158/1078-0432. CCR-07-2051
24. Ruiz C, Holz DR, Oeggerli M, Schneider S, Gonzales IM, Kiefer JM, Zellweger T, Bachmann A, Koivisto PA, Helin HJ, Mousses S, Barrett MT, Azorsa DO, Bubendorf L (2011) Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer. J Pathol 223(4):543-552. doi:10.1002/path.2828
25. Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM, Masters JR (2002) Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 198(2):237-244. doi:10.1002/path.1206 (Pubitemid 35243882)
26. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61(9):3550-3555 (Pubitemid 32694958)
27. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57(2):314-319 (Pubitemid 27036612)